

Our ref: FOI 1095

17<sup>th</sup> June 2022

## **FOI 1095 RESPONSE**

### **Question 1.**

**How many patients were treated by your Organisation (for any condition) in the last 3 months with the following drugs:**

**Adalimumab (Amgevita)**

**Adalimumab (Humira)**

**Adalimumab (Hyrimoz)**

**Adalimumab (Idacio)**

**Adalimumab (Imraldi)**

Adalimumab (Amgevita)	226
Adalimumab (Humira)	78
Adalimumab (Hyrimoz)	0
Adalimumab (Idacio)	0
Adalimumab (Imraldi)	559

### **Question 2.**

**How many patients were treated in the last 3 months by the Rheumatology department (for any condition) with the following drugs:**

**Adalimumab (Amgevita)**

**Adalimumab (Humira)**

**Adalimumab (Hyrimoz)**

**Adalimumab (Idacio)**

**Adalimumab (Imraldi)**

Adalimumab (Amgevita)	104
Adalimumab (Humira)	44
Adalimumab (Hyrimoz)	0
Adalimumab (Idacio)	0
Adalimumab (Imraldi)	315

**Question 3.**

**How many patients were treated in the last 3 months by the Dermatology department (for any condition) with the following drugs:**

**Adalimumab (Amgevita)**

**Adalimumab (Humira)**

**Adalimumab (Hyrimoz)**

**Adalimumab (Idacio)**

**Adalimumab (Imraldi)**

Adalimumab (Amgevita)	80
Adalimumab (Humira)	26
Adalimumab (Hyrimoz)	0
Adalimumab (Idacio)	0
Adalimumab (Imraldi)	110

Contact: [FOI.team@southerntrust.hscni.net](mailto:FOI.team@southerntrust.hscni.net)